Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
230.06
+0.31 (0.13%)
Jul 14, 2026, 9:45 AM EDT - Market open
Charles River Laboratories International Employees
Charles River Laboratories International had 19,700 employees as of December 31, 2025. The number of employees decreased by 400 or -1.99% compared to the previous year.
Employees
19,700
Change (1Y)
-400
Growth (1Y)
-1.99%
Revenue / Employee
$204,418
Profits / Employee
-$9,373
Market Cap
11.08B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 19,700 | -400 | -1.99% |
| Dec 31, 2024 | 20,100 | -1,700 | -7.80% |
| Dec 31, 2023 | 21,800 | 400 | 1.87% |
| Dec 31, 2022 | 21,400 | 1,400 | 7.00% |
| Dec 25, 2021 | 20,000 | 1,600 | 8.70% |
| Dec 26, 2020 | 18,400 | 1,300 | 7.60% |
| Dec 28, 2019 | 17,100 | 2,400 | 16.33% |
| Dec 29, 2018 | 14,700 | 2,900 | 24.58% |
| Dec 30, 2017 | 11,800 | 800 | 7.27% |
| Dec 31, 2016 | 11,000 | 2,400 | 27.91% |
| Dec 26, 2015 | 8,600 | 700 | 8.86% |
| Dec 27, 2014 | 7,900 | 200 | 2.60% |
| Dec 28, 2013 | 7,700 | 500 | 6.94% |
| Dec 29, 2012 | 7,200 | 100 | 1.41% |
| Dec 31, 2011 | 7,100 | -400 | -5.33% |
| Dec 25, 2010 | 7,500 | -500 | -6.25% |
| Dec 26, 2009 | 8,000 | -1,000 | -11.11% |
| Dec 27, 2008 | 9,000 | 500 | 5.88% |
| Dec 29, 2007 | 8,500 | 500 | 6.25% |
| Dec 30, 2006 | 8,000 | -400 | -4.76% |
| Dec 31, 2005 | 8,400 | 400 | 5.00% |
| Dec 25, 2004 | 8,000 | 3,500 | 77.78% |
| Dec 27, 2003 | 4,500 | -500 | -10.00% |
| Dec 28, 2002 | 5,000 | 1,000 | 25.00% |
| Dec 29, 2001 | 4,000 | 500 | 14.29% |
| Dec 30, 2000 | 3,500 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Labcorp Holdings | 71,000 |
| Quest Diagnostics | 57,000 |
| ICON Public Limited Company | 40,100 |
| Revvity | 11,000 |
| RadNet | 9,276 |
| Medpace Holdings | 6,200 |
| Qiagen | 5,700 |
| Sotera Health Company | 3,000 |
CRL News
- 1 day ago - Charles River announces collaboration with Arovella Therapeutics - TheFly
- 1 day ago - Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches - Business Wire
- 1 day ago - Charles River price target raised to $230 from $192 at Mizuho - TheFly
- 5 days ago - Charles River price target raised to $260 from $220 at Morgan Stanley - TheFly
- 6 days ago - Citi adds ‘upside 90-day catalyst watch’ on Charles River - TheFly
- 10 days ago - Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 26 days ago - Charles River to collaborate with AI/ML drug discovery platform Lilly TuneLab - TheFly
- 26 days ago - Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise - Business Wire